Table 1.

The description of ART cycles and characteristics of oocytes, fertility, and cleavage

Characteristic	Cycle 1	Cycle 2
Date	1/2016	6/2016
Protocol	GnRH agonist, long protocol	GnRH antagonists (ganirelix), fixed
Gonadotropin	r-FSH	hMG
Initiation dose (IU)	150	150
Duration of simulation (d)	9 (150 IU) + 2 (100 IU)	9 (150 IU)
Total dose of gonadotropin (IU)	1550	1350
On the day of hCG injection
Serum E2 level(pg/ml)	> 4839	4048
Serum Progesterone level(ng/ml)	1.50	0.81
Serum LH level (IU/L)	1.38	1.50
No. of total follicles	29	22
No. of the leading follicles (≥ 18 mm)	7	10
Ovulation triggering (dose)	250 μg (r-hCG)	10,000 IU (hCG) + 0.2 mg (GnRH agonist)
Time interval between hCG administration and oocyte retrieval (h)	36	36
No. of retrieved oocytes	17	14
No. of MII oocytes	12	10
No. of fertilization oocytes	7	7
No. of normal fertilization oocytes (2PN)	6	7
No. of cleavage embryos	0	0

r-FSH (recombinant FSH, Puregon®, Organon, Netherlands); GnRH antagonist, ganirelix (Orgalutran®, Organon, Netherlands); r-hCG (recombinant hCG, Ovidrel®, Merck Serono, Italy); hMG (Menopur®, Ferring, Germany); hCG (Livzon, China); GnRH agonist, Triptorelin acetate (Diphereline, Ipsen Pharma Biotech); OPU, ovum pick up